UnknownPhase 3

3DCRT vs. IMRT in Early Breast Cancer

South Korea690 participantsStarted 2015-05

Plain-language summary

It has been not clinically determined whether TomoDirect was dosimetrically better than 3D-CRT for Asian patients with early breast cancer. Therefore, the objective of this study was to compare dosimetric parameters of TomoDirect and 3D-CRT in early breast cancer patients of an Asian cohort.

Who can participate

Age range20 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. histologically confirmed breast cancer after breast-conserving surgery
✓. pT1-2N0
✓. no evidence of distant metastasis
✓. no previous malignancy
✓. patient age, 20 - 80 years
✓. Karnofsky performance score ≥ 70
✓. adequate bone marrow, liver, and renal function (leucocytes \> 4,000/mm3, hemoglobin \> 10 g/dL, platelets \> 100,000/mm3; serum bilirubin \< 1.5 mg/dL, serum transaminase \< 2.5 times the upper normal limit; serum creatinine \< 1.5 mg/dL).
✓. completion of scheduled chemotherapy

Exclusion criteria

✕. carcinoma in situ of breast
✕. distant metastasis
✕. mastectomy
✕. male
✕. both breast cancer

What they're measuring

Disease-free survival

Timeframe: 3-year

Trial details

NCT IDNCT02440191

SponsorJong Hoon Lee

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-04

Contact for this trial

Jong Hoon Lee, MD

010-8607-1269 koppul@catholic.ac.kr

View on ClinicalTrials.gov More Radiation Toxicity trials